Preclinical Antitumor Activity of BMS-599626, a Pan-Her Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-06-0642
Full Text
Open PDFAbstract
Available in full text
Date
October 15, 2006
Authors
Publisher
American Association for Cancer Research (AACR)